Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Cash & Equivalents (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Cash & Equivalents for 4 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents fell 8.29% to $7.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Sep 2025, down 8.29% year-over-year, with the annual reading at $7.5 million for FY2025, 8.29% down from the prior year.
  • Cash & Equivalents hit $7.5 million in Q3 2025 for Jin Medical International, down from $8.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.1 million in Q3 2024 to a low of $4.8 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $6.8 million across 4 years, with a median of $7.2 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 44.59% in 2023 and later decreased 8.29% in 2025.
  • Year by year, Cash & Equivalents stood at $4.8 million in 2022, then soared by 44.59% to $6.9 million in 2023, then grew by 17.41% to $8.1 million in 2024, then fell by 8.29% to $7.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for ZJYL at $7.5 million in Q3 2025, $8.1 million in Q3 2024, and $6.9 million in Q3 2023.